HPK1 / MAP4K1 (hematopoietic progenitor kinase 1)

Class

Small-molecule HPK1 (MAP4K1) kinase inhibitor

Pathway

Relieves HPK1-mediated suppression of TCR/BCR signaling, enhancing T-cell and dendritic cell antitumor immune activity

HPK1, also called MAP4K1, is an intracellular enzyme that acts as a brake on immune cell activation. It belongs to a family of kinases that add phosphate groups to other proteins, thereby changing their activity. In T cells and B cells, HPK1 dampens signaling that begins at the antigen receptor (the T-cell receptor, TCR, or B-cell receptor, BCR), and it similarly restrains dendritic cells, the immune cells that present antigens and prime T-cell responses. Because tumors often exploit inhibitory signals to keep nearby immune cells quiet, removing a brake like HPK1 is an attractive strategy: a small-molecule inhibitor that blocks HPK1's enzymatic activity is expected to restore or strengthen T-cell and dendritic cell responses against cancer. This mechanism sits within the broader category of immune-checkpoint and immune-agonist approaches used in oncology, distinct from checkpoint antibodies in that it acts inside the cell rather than at a surface receptor. The general rationale for pursuing this target is to counteract T-cell exhaustion and insufficient antitumor immunity, potentially complementing other immunotherapies. As an intracellular negative regulator broadly expressed across hematopoietic lineages, modulating HPK1 carries the possibility of amplifying immune activity systemically, which is a consideration in how such inhibitors are developed and monitored.